Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415194 · ClinicalTrials.gov registry record · Phase 3
A Study for Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
NCT00415194: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT00415194 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 795 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00415194, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
Study Summary
This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.
Primary Outcome
OS duration is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date, OS duration will be censored at the date of the participant's last contact prior to that cut-off date.
Interventions
- DRUG placebo
- DRUG cisplatin
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00415194 record still lists
NCT00415194 is an interventional study that assigns participants to a tested intervention. The registered 795 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00415194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00415194 about?
NCT00415194 is a clinical study titled "A Study for Patients With Head and Neck Cancer". This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.
What is the current status of trial NCT00415194?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2006-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00415194?
The interventions under investigation include: placebo (DRUG), cisplatin (DRUG), pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00415194?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00415194's enrollment target sits among peer trials
795 428th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia